PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12203099-1	2002	PURPOSE: Preclinical data indicate that progestational agents (progesterone, medroxyprogesterone acetate and megestrol acetate) interact with p-glycoprotein (P-gp) and reverse P-gp-associated resistance to vinca alkaloids and other natural products.	Megestrol Acetate	109-126	ATP binding cassette subfamily B member 1	Homo sapiens	142-156	
12203099-1	2002	PURPOSE: Preclinical data indicate that progestational agents (progesterone, medroxyprogesterone acetate and megestrol acetate) interact with p-glycoprotein (P-gp) and reverse P-gp-associated resistance to vinca alkaloids and other natural products.	Megestrol Acetate	109-126	ATP binding cassette subfamily B member 1	Homo sapiens	158-162	
12203099-1	2002	PURPOSE: Preclinical data indicate that progestational agents (progesterone, medroxyprogesterone acetate and megestrol acetate) interact with p-glycoprotein (P-gp) and reverse P-gp-associated resistance to vinca alkaloids and other natural products.	Megestrol Acetate	109-126	ATP binding cassette subfamily B member 1	Homo sapiens	176-180	
9484821-0	1998	Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma.	Megestrol Acetate	66-83	ATP binding cassette subfamily B member 1	Homo sapiens	98-112	
9625385-7	1998	This biological activity is thought to be mediated through the unique binding of megestrol acetate to p-glycoprotein.	Megestrol Acetate	81-98	ATP binding cassette subfamily B member 1	Homo sapiens	102-116	
11106232-2	2000	In experimental systems, hormonal agents, including megestrol acetate (MA), have been shown to be capable of reversing P-glycoprotein-mediated multidrug resistance to natural products, including paclitaxel.	Megestrol Acetate	52-69	ATP binding cassette subfamily B member 1	Homo sapiens	119-133	
9484821-1	1998	The objective of this study was to determine if the addition of megestrol acetate (MA), a modulator of P-glycoprotein-mediated drug resistance, to first-line cytotoxic therapy in patients with limited and advanced stage small-cell lung cancer (SCLC) would improve median time to disease progression and median overall survival.	Megestrol Acetate	64-81	ATP binding cassette subfamily B member 1	Homo sapiens	103-117	
1348973-0	1992	Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein.	Megestrol Acetate	0-17	ATP binding cassette subfamily B member 1	Homo sapiens	67-81